Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
Richard Quek1, Suzanne George21Visiting Fellow, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 2Clinical Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USAAbstract: In the last decade a tremendous amount has been learne...
Main Authors: | Richard Quek, Suzanne George |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-02-01
|
Series: | Biologics : Targets & Therapy |
Online Access: | http://www.dovepress.com/update-on-the-treatment-of-gastrointestinal-stromal-tumors-gists-role--a3939 |
Similar Items
-
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01) -
Update on imatinib for gastrointestinal stromal tumors: duration of treatment
by: Linch M, et al.
Published: (2013-07-01) -
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
by: Adnan Asif Parvez Ghias, et al.
Published: (2018-03-01) -
Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
by: Isabelle Deshaies, et al.
Published: (2010-09-01) -
Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
by: Hiroyuki Sako, et al.
Published: (2014-01-01)